NDAINTRAVENOUSPOWDER
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
CARMUSTINE (carmustine) by Accord Biopharma is understood. First approved in 2022.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Carmustine is a nitrosourea alkylating agent administered intravenously as a powder formulation that alkylates DNA and RNA while also inhibiting key enzymatic processes through carbamoylation. It is indicated for various malignancies including brain tumors, lymphomas, and other cancers where alkylating chemotherapy is appropriate. The drug's metabolites contribute to both antitumor activity and associated toxicities.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30 score), suggesting stable team size and resource allocation in the brand organization.
Mechanism of Action
understood. While carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. The metabolites may contribute to antitumor activity and toxicities of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Started Mar 2025
49 enrolled
LymphomaNon-Hodgkin LymphomaHodgkin Lymphoma
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Started Aug 2022
50 enrolled
Glioblastoma Multiforme
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
Started Jun 2009
0Glioblastoma Multiforme
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
Started Jun 2008
7 enrolled
Glioma
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Started Aug 2003
118 enrolled
Glioblastoma
Worked on CARMUSTINE at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.